The Food and Drug Administration has accepted Lannett’s abbreviated new drug application for fluticasone propionate and salmeterol inhalation powder in three strengths — a generic of GlaxoSmithKline's ...
Corticosteroid + long-acting beta-2 agonist (LABA). Allow approx. 12hrs between doses. Asthma: ≥12yrs: initially 1 inh of 100/50 or 250/50 or 500/50 twice daily, based on disease severity and previous ...
Lannett has submitted an ANDA to the Food and Drug Administration for its strategic partner, Respirant's fluticasone propionate and salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) ...
LONDON, April 20, 2021 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that it has resumed the launch of its generic version of GlaxoSmithKline's ...
GlaxoSmithKline plc (GSK) today announced results from the 'LABA' (long acting beta 2-agonist) safety study, AUSTRI(SAS115359). The study compared Advair ® Diskus ®, a combination of the LABA, ...
Please provide your email address to receive an email when new articles are posted on . The FDA recently issued approval to the first generic version of ...
HERTFORDSHIRE, England, and PITTSBURGH, Feb. 19, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that its abbreviated new drug application (ANDA) for fluticasone propionate 100, ...
A number of well-known GlaxoSmithKline drugs, including one major blockbuster, will no longer be covered by the largest pharmacy benefit manager in the U.S. beginning Jan. 1. The pharmacy benefit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results